ReCode Therapeutics Raises Additional USD50M in Series B Financing
Summary
Kouki Harasaki, Ph.D., founding and managing partner of Bioluminescence Ventures (BLV), joined the company’s board of directors. The company intends to use the funds to advance its primary ciliary dyskinesia and cystic fibrosis clinical development programs and to expand its proprietary Selective Organ Targeting (SORT) lipid nanoparticle (LNP) pipeline to include mRNA and gene correction therapeutics for central nervous system, lung, liver and musculoskeletal indications. Its Selective Organ Targeting (SORT) lipid nanoparticle (LNP) platform enables precise and targeted delivery of genetic medicines directly to the organs and cells implicated in disease, enabling improved efficacy and potency. Its lead programs include RCT1100 for the treatment of primary ciliary dyskinesia caused by pathogenic mutations in the DNAI1 gene, and RCT2100 for the treatment of the 10-13 percent of cystic fibrosis patients who have Class I mutations in the CFTR gene and do not respond to currently approved CFTR modulators. RCT1100 and RCT2100 are inhaled disease-modifying mRNA-based therapies formulated using the SORT LNP delivery platform.
Funding
Review available funding amount, funding date, investors, and linked company information related to ReCode Therapeutics Raises Additional USD50M in Series B Financing in the interactive ISVWorld profile.